RALEIGH, N.C., Aug. 9 /PRNewswire/ -- Micell Technologies announced an expansion of its license agreement for using supercritical fluids for creating medical device surface modifications with Pacific Northwest National Laboratory, a U.S. Department of Energy laboratory, managed by Battelle. Under the expansion of the agreement, research will focus on additional applications of the award winning e-RESS technology for creating drug-eluting coatings for cardiovascular stents.
The e-RESS (e for electrostatic, RESS for Rapid Expansion from Supercritical Solution) innovation involves electrostatic capture and deposition of micro and nanoparticles onto the surface of a medical device using supercritical fluids. Scientists at Micell and PNNL were recently honored with a prestigious R&D 100 Award recognizing the technology as one of the 100 most important scientific and technical innovations for 2006. The e-RESS technology has been exclusively licensed to Micell from PNNL, and all product developed through this expanded agreement will be licensed to Micell under the terms of the current agreement.
“Combining PNNL’s expertise in supercritical fluid technology with our internal expertise creates a powerful combination for continued development of this unique medical device surface modification technology,” said Arthur J. Benvenuto, Chairman and Chief Executive Officer of Micell Technologies. “Micell’s processes utilizing the e-RESS technology create an opportunity to deliver the next generation of drug-eluting stents, and to provide the potential for further important advances to the medical device marketplace.”
About Pacific Northwest National Laboratory
Pacific Northwest National Laboratory (PNNL) is a Department Of Energy, Office of Science laboratory that solves complex problems in energy, national security, the environment and life sciences by advancing the understanding of physics, chemistry, biology and computation. PNNL employs 4,200 staff, has an annual budget of more than $725 million, and has been managed by Ohio-based Battelle since the lab’s inception in 1965. To learn more, please visit PNNL’s website at www.pnl.gov/
About Micell
Micell Technologies is a privately-held, early-stage biomedical company dedicated to advancing combination product therapies in the cardiovascular, orthopedic, and drug-delivery areas. The Company’s patented processes and methods for medical device surface modification using supercritical fluids are focused on improvements to current polymer based drug-eluting technologies. To learn more, please visit our website at www.micell.com
Micell Technologies
CONTACT: James McClain Ph.D., Chief Technology Officer of MicellTechnologies, +1-919-313-2111; or Mary Anne Wuennecke, Media Relations ofPacific Northwest National Laboratory, +1-509-375-2447
